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reanalysis of data from meta-analyses up to 2010
Karina Karolina Kedzior* and Sarah Kim ReitzAbstract
Background: According to a narrative review of 13 meta-analyses (published up to 2010), repetitive transcranial
magnetic stimulation (rTMS) has a moderate, short-term antidepressant effect in the treatment of major depression.
The aim of the current study was to reanalyse the data from these 13 meta-analyses with a uniform meta-analytical
procedure and to investigate predictors of such an antidepressant response.
Methods: A total of 40 double-blind, randomised, sham-controlled trials with parallel designs, utilising rTMS of the
dorsolateral prefrontal cortex in the treatment of major depression, was included in the current meta-analysis. The
studies were conducted in 15 countries on 1583 patients and published between 1997–2008. Depression severity
was measured using the Hamilton Depression Rating Scale, Beck Depression Inventory, or Montgomery Åsberg
Depression Rating Scale at baseline and after the last rTMS. A random-effects model with the inverse-variance
weights was used to compute the overall mean weighted effect size, Cohen’s d.
Results: There was a significant and moderate reduction in depression scores from baseline to final, favouring
rTMS over sham (overall d = −.54, 95% CI: −.68, −.41, N = 40 studies). Predictors of such a response were investigated
in the largest group of studies (N = 32) with high-frequency (>1 Hz) left (HFL) rTMS. The antidepressant effect of
HFL rTMS was present univariately in studies with patients receiving antidepressants (at stable doses or started
concurrently with rTMS), with treatment-resistance, and with unipolar (or bipolar) depression without psychotic
features. Univariate meta-regressions showed that depression scores were significantly lower after HFL rTMS in studies
with higher proportion of female patients. There was little evidence for publication bias in the current analysis.
Conclusions: Daily rTMS (with any parameters) has a moderate, short-term antidepressant effect in studies
published up to 2008. The clinical efficacy of HFL rTMS may be better in female patients not controlling for any other
study parameters.
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Repetitive transcranial magnetic stimulation (rTMS) is
an effective treatment against medication-resistant uni-
polar depression. According to a narrative review of
13 meta-analyses (published between 2001–2010), the
clinically-meaningful effect of daily rTMS of the dorsolat-
eral prefrontal cortex (DLPFC) was observed in double-
blind, randomised-controlled trials (RCTs) with inactive
sham groups, published between 1995–2008 (Dell’Osso* Correspondence: kkedzior@graduate.uwa.edu.au
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article, unless otherwise stated.et al. 2011). According to these meta-analyses, such an ef-
fect was investigated mostly in the short-term (baseline to
last rTMS session) treatment of major depression, during
the double-blind phases of RCTs.
Regardless of such a high interest in this topic, the
antidepressant effect of rTMS was found to be moderate
and rTMS parameters of clinical relevance were only par-
tially established in the past 13 meta-analyses (Dell’Osso
et al. 2011). The past meta-analyses showed that the
short-term antidepressant effect was most consistently ob-
served in the largest subgroup of RCTs using the high fre-
quency (>1 Hz) left (HFL) stimulation of the DLPFCntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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analyses (based on a small number of RCTs) showed that
the low frequency (≤1 Hz) right (LFR) rTMS and bilateral
(or sequential) rTMS also appear to have antidepressant
properties in the short-term (Herrmann and Ebmeier
2006; Schutter 2010; Slotema et al. 2010). Regardless of
frequency/location, the antidepressant effect of rTMS oc-
curred after 10 or 15 sessions of treatment (Gross et al.
2007; Martin et al. 2003; Rodriguez-Martin et al. 2001).
However, there was no association between the anti-
depressant effect and the duration of treatment nor any
other rTMS parameters, such as the frequency of stimula-
tion, resting motor threshold, stimuli/session, or total
stimuli/study (Herrmann and Ebmeier 2006; Holtzheimer
et al. 2001; Schutter 2009; Slotema et al. 2010).
Similarly to rTMS parameters, the demographic and
clinical predictors of rTMS response were not consist-
ently established in the past 13 meta-analyses (Dell’Osso
et al. 2011). For example, effect sizes were unrelated to
the mean age of patients (Herrmann and Ebmeier 2006).
Furthermore, rTMS was effective as a monotherapy, in
studies with patients on concurrent antidepressants (Burt
et al. 2002; Herrmann and Ebmeier 2006; Slotema et al.
2010), and in studies with treatment-resistant patients
(Herrmann and Ebmeier 2006; Lam et al. 2008; Schutter
2009). The authors of some meta-analyses suggested
that the antidepressant effect of rTMS could be en-
hanced in less severely resistant patients (Gross et al.
2007; Holtzheimer et al. 2001). Finally, the antidepres-
sant effect of rTMS was observed in studies with uni-
polar and bipolar patients (Dell’Osso et al. 2011) and
non-psychotic patients (Slotema et al. 2010).
It is not surprising that consistent outcomes were not
observed considering the heterogeneous aims and ap-
proaches to meta-analysis utilised in the past 13 meta-
analyses up to 2010. In general, all 13 meta-analyses were
published before the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines were
established (Moher et al. 2009). These guidelines were
established to improve the quality of systematic reviews in
terms of consistent reporting of all steps of such reviews,
including the literature search procedures, study selection,
assessment of publication bias, description of statistical
details of the analyses, and presenting of results (Moher
et al. 2009) and have been implemented in the newest
meta-analyses on this topic published after 2010 (for re-
view see Kedzior et al. 2014). Our inspection of the 13
meta-analyses up to 2010 revealed that, although similar
databases, search terms, and timeframes were used, the
analyses included a different number of primary studies
published between 1995–2008 (for more details see
Additional file 1). Some overlap in the primary studies
suggests that similar inclusion and exclusion criteria
were applied although specific aims differed among the13 meta-analyses. Furthermore, except for one study
(Holtzheimer et al. 2001), the statistical approach was
not adequately described in the 13 meta-analyses. It was
especially unclear how baseline depression scores were
controlled for when computing effect sizes in most of
the 13 meta-analyses. Since many studies utilised differ-
ent rTMS parameters in multiple subgroups of patients
(with only one sham group/study), multiple depression
scales, and multiple points in time (baseline and final),
the statistical approach to reducing such complex data
sets to single effect sizes/study should be adequately ex-
plained to better understand the reliability of results.
Based on the random selection of all available studies
on this topic, the correct (more statistically conserva-
tive) random-effects model of meta-analysis was applied
in most of the 13 meta-analyses. However, the weighting
method of effect sizes was often not explicitly explained.
Since studies with positive and significant effect sizes
are more likely to be submitted for peer-review and
published (Borenstein et al. 2009), a resulting publica-
tion bias was assessed, although inconsistently (using
different tests), in the 13 meta-analyses. Finally, since
too few homogenous studies were available for moder-
ator analyses (subgroup analyses or meta-regressions),
such analyses were either not conducted at all or, if con-
ducted, the statistical power to detect any significant
predictors was often low.
Therefore, the aim of the current study was to apply a
uniform and transparent (explicitly described) meta-
analytical procedure to reanalyse the data from the past
13 meta-analyses (published until 2010 and conducted
using heterogeneous statistical methods). Although such
a reanalysis could be considered a replication rather than
a novel study, replications are necessary in science to
more reliably confirm or synthesise the findings of others
(Laws 2013). In particular, our aim was to find out if the
reanalysis of data from the primary studies published until
2008 with one method of meta-analysis would produce
only a moderate short-term antidepressant effect of rTMS
(like the one observed in most of the past 13 meta-
analyses) or if the effect would increase due to a uniform
statistical approach used in this overall meta-analysis. It
was also of interest to test if the inclusion of more data
than any one of the past meta-analyses alone would allow
us to detect any significant predictors of the short-term
response to rTMS due to a higher statistical power of such
an overall analysis. The choice of predictors was based on
the data presented in the past 13 meta-analyses and
included clinical and demographic characteristics of
patients and parameters of rTMS. In addition, we have
included gender (measured as percentage of female pa-
tients/study) as another predictor because none of the
past 13 meta-analyses investigated the relationship be-
tween gender and the response to rTMS although
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worldwide (Bromet et al. 2011). The update of the current
meta-analysis using data from primary RCTs identified in
a novel systematic literature search and published after
2008 was published recently (Kedzior et al. 2014).
It was hypothesised that, when controlling for baseline,
a significant antidepressant effect favouring rTMS over
sham would be observed in HFL, LFR, and bilateral/se-
quential studies based on the findings from the past 13
meta-analyses. If statistical heterogeneity alone were to
blame for relatively low effect sizes in the 13 meta-
analyses then it was expected that the effect sizes would
be higher utilising one uniform method of meta-analysis
in the current study. Finally, we expected to find signifi-
cant predictors of antidepressant response to rTMS (pa-
tient characteristics and/or rTMS parameters) due to the
improved statistical power resulting from the highest
number of studies included in the current compared to
the past meta-analyses.
Methods
The PRISMA checklist listing the precise location of
various steps of this meta-analysis is included in the
Additional file 1.
Study Selection
The primary studies used in the current meta-analysis
were selected from the past 13 meta-analyses published
between 2001–2010 (Dell’Osso et al. 2011). The details
of the systematic literature search strategy used in each of
these 13 meta-analyses are summarised in the Additional
file 1: Table S1. Most past meta-analyses utilised Medline
or PubMed databases and similar search terms including
‘depression’ and ‘rTMS’.
Various combinations of N = 53 primary sources pub-
lished between 1995–2008 were included in the past 13
meta-analyses (see the Additional file 1: Table S2). The
study selection procedure and exclusion criteria used
in the current meta-analysis are summarised in the
PRISMA flowchart (Moher et al. 2009), Figure 1. Studies
were excluded mostly because inadequate data were re-
ported to compute the effect sizes and the authors failed
to reply to email requests and/or provide additional
data. The final meta-analysis was performed on the data
from 40 out of 53 studies which met the following inclu-
sion criteria:
 double-blind RCT with an inactive sham group,
 parallel design (cross-over designs might produce
data biased by carry-over effects and thus such data
were excluded from the current analysis),
 active rTMS (with any frequency of stimulation) and
sham administered at the same DLPFC location
(left, right, bilateral or sequential), patients with primary diagnoses of major depressive
episode or disorder according to DSM-IV and/or
ICD-10 criteria (unipolar or bipolar, non-psychotic
or psychotic),
 depression measured at baseline and on the last
session of rTMS or sham during the double-blind
phase of a study,
 depression measured according to any version of
Hamilton Depression Rating Scale, HAMD
(Hamilton 1960), Beck Depression Inventory, BDI
(Beck et al. 1961), or Montgomery Åsberg
Depression Rating Scale, MADRS (Montgomery and
Asberg 1979),
 adequate data provided to compute effect sizes or
author contact details available for additional data
requests.
Data extraction
Data were extracted from all N = 40 RCTs by both
authors independently and any inconsistencies were re-
solved between the authors via consensus. In some cases
depression scores were extrapolated from figures (using
physical measurements of the printed figures) by both
authors independently and a mean of both estimations
was used in the final analyses. The extracted data were
also cross-checked against the data shown in the past 13
meta-analyses. The rTMS parameters, clinical character-
istics of patients, and mean depression scores (baseline
and final in rTMS and sham groups) are shown in Tables 1
and 2 respectively.
Meta-Analysis
The mathematical approach used in the current meta-
analysis is explained in detail in the Additional file 1. In
general, the current study utilised the random-effects
model of meta-analysis with inverse-variance weights
(Borenstein et al. 2009) using Comprehensive Meta-
Analysis 2.0 (CMA; Biostat Inc., USA) and SPSS-21 (IBM
Corp., USA). The random-effects model was chosen be-
cause it was assumed that
1. the primary studies included in the current analysis
were a random sample of all studies on the topic,
2. the effect sizes of those studies would differ based
on the heterogeneous rTMS parameters and/or
clinical characteristics of patients (Tables 1 and 2),
3. results from studies in the current meta-analysis
could be extrapolated to a wider population of
patients with major depression.
One important assumption of any meta-analysis is that
each study is independent of all other studies in the
analysis and thus contributes only one effect size to the
computation of the overall mean weighted effect size
Figure 1 Study selection and exclusion criteria. Note: Abbreviations: DLPFC, dorsolateral prefrontal cortex; N, number of sources.
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tiple rTMS groups with different parameters (such as
two high frequencies of 5 Hz and 20 Hz), then the de-
pression scores from both rTMS groups were combined
into one (for formulae see the Additional file 1).
In the first step of the analysis, one effect size was
computed for each study. The effect size used in the
current meta-analysis was the standardised mean differ-
ence (Cohen’s d), which was computed as follows:
d ¼ sham ðmean standardised depression score at
baseline – final sessionÞ – active rTMS
ðmean standardised depression score at
baseline – final sessionÞ:
The interpretation criteria for the absolute size of
Cohen’s d are: d = .20-.49 (low), d = .50-.79 (moderate),
and d ≥ .80 (high) (Cohen 1988). Since Cohen’s d is often
inflated in studies conducted on small samples, a stan-
dardised mean difference corrected for the sample size,
Hedges’ g, was also computed (Borenstein et al. 2009);
for the formula refer to the Additional file 1.
In the second step of the analysis, each effect size was
weighted based on the inverse of the sum of the within-and between-study variance (DerSimonian and Laird
1986). The logic behind this weighing method is that
studies with a high variability of scores (high variance,
low precision) contribute only a small weight to the over-
all mean weighted effect size and vice-versa.
In the final step of the analysis, one overall mean
weighted effect size of all studies was computed as the
sum of the product of all effect sizes and weights divided
by the sum of all weights (Borenstein et al. 2009). Ac-
cording to our calculation, negative values of the overall
mean weighted effect sizes (d or g and their 95% confi-
dence intervals, 95% CIs) indicate that depression scores
are reduced on the final session compared to baseline,
favouring rTMS over sham.
Heterogeneity among effect sizes was tested using a Q
statistic and an I2 index (Borenstein et al. 2009). The Q
statistic tests the null-hypothesis that there is homogen-
eity among effect sizes in the analysis (Q = 0). However,
the interpretation of the null-hypothesis testing is prone
to Type I and Type II statistical errors and thus cannot
be used as a reliable measure of heterogeneity alone.
Instead, the Q statistic can be expressed on a 0-100%
scale using the so-called I2 index (I2 = 100% × (Q-df )/Q
with df =N-1; N = number of studies). The I2 index can
Table 1 rTMS parameters in the N = 40 RCTs included in the current meta-analysis























George et al. (1997); USAa L 5 cm 20 80 F8 – 45 800 – 58 10 Cadwell
Avery et al. (1999); USA L 5 cm 10 80 – – 45 – 20 55 10 Cadwell
Kimbrell et al. (1999); USAa L 5 cm 20 80 F8 – 45 800 20 60 10 Cadwell
L 1
Klein et al. (1999); Israel R 6 cm 1 110 C 90 90 120 – 180 10 Cadwell
Loo et al. (1999); Australia L 5 cm 10 110 F8 70 45 – 30 30 10 MagStim
Padberg et al. (1999); Germany L 5 cm 10 90 F8 70 90 250 5 30 5 MagStim
L .3 10
Berman et al. (2000); USA L 5 cm 20 80 F8 – 45 – 20 58 10 Cadwell
Eschweiler et al. (2000); Germanya,b L 5 cm 10 90 F8 70 90 – 20 50 5 MagStim
George et al. (2000); USAc L 5 cm 12* 100 F8 – 45 1600 – 25* 10 Cadwell
Garcia-Toro et al. (2001a); Spain L 5 cm 20 90 F8 – 90 – 30 30* 10 MagPro
Garcia-Toro et al. (2001b); Spain L 5 cm 20 90 F8 85 90 1200 30 30* 10 MagPro
Manes et al. (2001) ; USA L MRI 20 80 F8 – TI – 20 60 5 MagStim
Boutros et al. (2002); USA L 5 cm 20 80 F8 70 90 800 20 58 10 MagStim
Padberg et al. (2002); Germanyd L 5 cm 10 100 F8 70 90 1500 15 30 10 MagStim
Fitzgerald et al. (2003); Australia L 5 cm 10 100 F8 70 45 1000 20 25 10 MagStim
R 1 300 5 60
Höppner et al. (2003); Germanye L 5 cm 20 90 F8 – 90 – 20 60 10 MagLite
Loo et al. (2003); Australia B 5 cm 15 90 F8 70 TI – 24 25 15 MagStim
Nahas et al. (2003); USA L 5 cm 5 110 F8 – 45 1600 – 22 10 Neotonus
Buchholtz et al. (2004); Denmark L 5 cm 10 90 F8 70 90 – 20 60 15 MagStim
Hausmann et al. (2004); Austriaf BS MRI 11* 110* F8 – TI 2300* 10 10 10 MagStim
Holtzheimer et al. (2004); USA L 5 cm 10 110 F8 – 45 1600 32 45* 10 MagPro
Kauffmann et al. (2004); USA R 5 cm 1 110 C 90 45 120 2 180 10 MagLite
Koerselman et al. (2004); Netherlands L 5 cm 20 80 C 60 45 – 20 30 10 MagPro
Mosimann et al. (2004); Switzerland L 5 cm 20 100 F8 – 90 1600 40 28 10 MagStim
Poulet et al. (2004); France L 5 cm 10 80 F8 70 45 – 20 58 10 MagStim
Rossini et al. (2005); Italy L 5 cm 15 100 F8 70 90 900 30 28 10 MagStim
Rumi et al. (2005); Brazil L 5 cm 5 120 F8 – TS 1250 25 20 20 MagPro


















Table 1 rTMS parameters in the N = 40 RCTs included in the current meta-analysis (Continued)
Avery et al. (2006); USA L MRI 10 110 F8 70 90 1600 32 28* 15 MagPro
Fitzgerald et al. (2006); Australia BS 5 cm 6* 105* F8 70 45 – 18 28* 10 MagPro
Garcia-Toro et al. (2006); Spaing BS 5 cm 11* 110 F8 85 45 – 60 20* 10 MagPro
Januel et al. (2006); France R 5 cm 1 90 F8 – TS – 2 180 16 MagStim
Anderson et al. (2007); UK L 5 cm 10 110 F8 – TS 1000 20 30 12 MagStim
Bortolomasi et al. (2007); Italy L 5 cm 20 90 C 90 90 800 20 60 5 MagStim
Herwig et al. (2007); Germany/Austriah L F3 10 110 F8 70 45 2000 100 8 15 MagStim/Pro
Loo et al. (2007); Australiai L 5 cm 10 110 F8 70 TI – 30 25 20 MagStim
O’Reardon et al. (2007); USA, Australia,
Canada
L 5 cm 10 120 – – TS 3000 – 26 20 Neuronetics
Stern et al. (2007); USA L 5 cm 10 110 F8 – 90 – 20 52 10 MagStim/MagPro
L 1 1 –
R 1 1 –
Bretlau et al. (2008); Denmark L 5 cm 8 90 F8 70 TS 1289 20 52 15 MagStim
Mogg et al. (2008); UK L 5 cm 10 110 F8 – TS 1000 20 55 10 MagStim
Notes: *Mean values. Sham was always administered at the same DLPFC location (left or right or bilateral) as the active rTMS (for the definition of DLPFC location, ‘5 cm’ refers to 5 cm rostral (anterior) to sagittal
(parasagittal) plane). aIf cross-over design was used then the results of only the parallel double-blind stimulation are included in the current analysis. bThe combined scores of two active rTMS groups (group 1 and 3)
are included in the current analysis. cThe combined scores of two HFL rTMS groups (5 Hz and 20 Hz) are included in the current analysis. dSince sham was administered at 100% MT, only the active rTMS with 100%
MT group is included in the current analysis. eSince sham was administered to the left DLPFC, only the HFL rTMS group is included in the current analysis. fThe ‘active rTMS’ group consists of group A1 (HFL rTMS
followed by right-sham) and group A2 (HFL rTMS followed by LFR rTMS). Sham was applied bilaterally (left then right DLPFC). g’Active TMS’ group is included in the current analysis (active TMS after single photon
emission computed tomography, SPECT, is excluded because patients in this group received rTMS at individualised sites based on the results of SPECT). hSham was administered 5 cm lateral to the F3 location, above
the left temporal muscle. iIn contrast to all other studies that utilised a single rTMS (or sham) session/day, rTMS was applied twice/day for 2 weeks, 5 days/week (thus a total of 20 sessions). Abbreviations: B, bilateral
DLPFC; BS, bilateral sequential (left then right DLPFC); C, circular; DLPFC, dorsolateral prefrontal cortex; F3, the F3 location of the 10–20 electroencephalogram (EEG) system; F8, figure-of-eight shape; L, left DLPFC; MRI,


































ScaleE Mean ± SD (number of patients) depression severity score
Baseline Last sessionF Baseline – last session
Sham rTMS Sham rTMS Sham rTMS
George et al.
(1997)
42 92% some + 8% N/A + Tab one HAMD21 26 ± 3 (5) 30 ± 4 (7) 30 ± 8 (5) 23 ± 9 (7) −4 ± 7 (5) 7 ± 8 (7)
Avery et al.
(1999)
44 83% + + 17% – + Tab one HAMD21 20 ± 8 (2) 21 ± 7 (4) 15 ± 2 (2) 11 ± 4 (4) 5 ± 7 (2) 10 ± 6 (4)
BDI21 20 ± 7 (2) 28 ± 7 (4) 14 ± 11 (2) 20 ± 11 (4) 6 ± 10 (2) 8 ± 10 (4)
Kimbrell et al.
(1999)
42 54% N/A + 31% N/A – All
(Tab one)
HAMD21 24 ± 7 (3) 30 ± 8 (10) 25 ± 10 (3) 27 ± 10 (10) −1 ± 9 (3) 3 ± 9 (10)
20Hz 24 ± 7 (3) 25 ± 7 (5) 25 ± 10 (3) 28 ± 8 (5) −1 ± 9 (3) −3 ± 8 (5)
1Hz 24 ± 7 (3) 34 ± 8 (5) 25 ± 10 (3) 27 ± 13 (5) −1 ± 9 (3) 7 ± 11 (5)
Klein et al.
(1999)
59 76% – + 19% + 23% + Tab two HAMD17 25 ± 6 (32) 26 ± 6 (35) 20 ± 10 (32) 14 ± 9 (35) 5 ± 9 (32) 12 ± 8 (35)
MADRS 34 ± 8 (32) 34 ± 5 (35) 27 ± 12 (32) 20 ± 12 (35) 7 ± 11 (32) 14 ± 10 (35)
Loo et al.
(1999)
48 50% some + 17% + 6% + Authors HAMD21 25 ± 6 (9) 21 ± 7 (9) 19 ± 7 (9) 17 ± 7 (9) 6 ± 7 (9) 4 ± 7 (9)
MADRS 38 ± 6 (9) 33 ± 9 (9) 29 ± 10 (9) 26 ± 9 (9) 9 ± 9 (9) 7 ± 9 (9)
Padberg et al.
(1999)
51 61% + – N/A + All HAMD21 22 ± 9 (6) 28 ± 9 (12) 24 ± 10 (6) 25 ± 8 (12) −2 ± 10 (6) 3 ± 8 (12)
Text 10Hz 22 ± 9 (6) 30 ± 10 (6) 24 ± 10 (6) 28 ± 9 (6) −2 ± 10 (6) 2 ± 10 (6)
Fig one
0.3Hz
22 ± 9 (6) 27 ± 9 (6) 24 ± 10 (6) 22 ± 6 (6) −2 ± 10 (6) 5 ± 8 (6)
Berman et al.
(2000)
42 30% some + 5% + 5% – Tab one HAMD25 37 ± 8 (10) 37 ± 10 (10) 36 ± 9 (10) 25 ± 9 (10) 1 ± 8 (10) 12 ± 10 (10)
Eschweiler
et al. (2000)
57 67% N/A – + 8% + Tab one HAMD21 20 ± 4 (5) 27 ± 4 (7) 23 ± 6 (5) 22 ± 5 (7) −3 ± 5 (5) 5 ± 5 (7)
BDI21 28 ± 10 (5) 40 ± 6 (7) 32 ± 9 (5) 33 ± 11 (7) −4 ± 10 (5) 7 ± 10 (7)
George et al.
(2000)
44 63% N/A + 30% – – All
(Tab one)
HAMD21 24 ± 4 (10) 28 ± 6 (20) 19 ± 6 (10) 18 ± 9 (20) 5 ± 5 (10) 10 ± 8 (20)
Garcia-Toro
et al. (2001a)
51 43% + – N/A + Tab two HAMD21 26 ± 5 (18) 27 ± 7 (17) 24 ± 4 (18) 20 ± 6 (17) 2 ± 5 (18) 7 ± 7 (17)
BDI17 26 ± 6 (18) 27 ± 9 (17) 24 ± 5 (18) 22 ± 7 (17) 2 ± 6 (18) 5 ± 8 (17)
Garcia-Toro
et al. (2001b)
44 55% – N/A N/A +D1 Tab one HAMD21 27 ± 6 (11) 26 ± 6 (11) 18 ± 9 (11) 16 ± 8 (11) 9 ± 8 (11) 10 ± 7 (11)
BDI17 23 ± 7 (11) 27 ± 8 (11) 21 ± 8 (11) 19 ± 7 (11) 2 ± 8 (11) 8 ± 8 (11)
Manes et al.
(2001)
61 50% some N/A N/A – Tab two HAMD21 23 ± 7 (10) 23 ± 5 (10) 16 ± 8 (10) 14 ± 5 (10) 7 ± 8 (10) 9 ± 5 (10)
Boutros et al.
(2002)
51 22% + – N/A + Tab two HAMD25 36 ± 4 (7) 40 ± 10 (11) 26 ± 13 (7) 27 ± 13 (11) 10 ± 12 (7) 13 ± 12 (11)
Padberg et al.
(2002)
57 70% + N/A N/A + All (Tab one,
Fig two)
HAMD21 24 ± 6 (10) 24 ± 6 (10) 22 ± 6 (10) 17 ± 9 (10) 2 ± 6 (10) 7 ± 8 (10)
MADRS 30 ± 6 (10) 29 ± 6 (10) 29 ± 6 (10) 19 ± 9 (10) 1 ± 6 (10) 10 ± 8 (10)
Fitzgerald
et al. (2003)


















Table 2 Patient characteristics at baseline and depression scores in the active rTMS and sham groups in N = 40 RCTs (Continued)
BDI21 32 ± 9 (20) 34 ± 11 (40) 29 ± 9 (20) 27 ± 11 (40) 3 ± 9 (20) 7 ± 11 (40)
Tab two
10Hz
MADRS 36 ± 8 (20) 36 ± 8 (20) 35 ± 8 (20) 31 ± 8 (20) 1 ± 8 (20) 5 ± 8 (20)
BDI21 32 ± 9 (20) 33 ± 12 (20) 29 ± 9 (20) 27 ± 12 (20) 3 ± 9 (20) 6 ± 12 (20)
Tab two
1Hz
MADRS 36 ± 8 (20) 38 ± 8 (20) 35 ± 8 (20) 32 ± 9 (20) 1 ± 8 (20) 6 ± 8 (20)
BDI21 32 ± 9 (20) 35 ± 9 (20) 29 ± 9 (20) 27 ± 11 (20) 3 ± 9 (20) 8 ± 10 (20)
Höppner et al.
(2003)
59 70% N/A + 3% – + Fig two
20Hz
HAMD21 25 ± 8 (10) 22 ± 4 (10) 13 ± 8 (10) 14 ± 5 (10) 12 ± 8 (10) 8 ± 5 (10)
Fig one
20Hz
BDI21 28 ± 8 (10) 26 ± 7 (10) 22 ± 11 (10) 18 ± 8 (10) 6 ± 10 (10) 8 ± 8 (10)
Loo et al.
(2003)
52 79% some + 16% N/A + Authors HAMD17 20 ± 4 (10) 24 ± 5 (9) 16 ± 7 (10) 19 ± 8 (9) 4 ± 6 (10) 5 ± 7 (9)
MADRS 33 ± 5 (10) 38 ± 6 (9) 27 ± 10 (10) 31 ± 14 (9) 6 ± 9 (10) 7 ± 12 (9)
Nahas et al.
(2003)
43 61% N/A + 100% N/A – Authors HAMD28 33 ± 8 (12) 32 ± 4 (11) 24 ± 12 (12) 24 ± 12 (11) 9 ± 11 (12) 8 ± 11 (11)
Buchholtz
et al. (2004)
50 31% N/A + 23% N/A + Authors HAMD17 24 ± 5 (7) 26 ± 3 (6) 13 ± 10 (7) 16 ± 3 (6) 11 ± 9 (7) 10 ± 3 (6)
Hausmann
et al. (2004)
47 61% N/A N/A – +D1 Tab two HAMD21 34 ± 4 (13) 32 ± 6 (25) 22 ± 8 (13) 18 ± 9 (25) 12 ± 7 (13) 14 ± 8 (25)
BDI13 31 ± 12 (13) 32 ± 10 (25) 21 ± 14 (13) 17 ± 12 (25) 10 ± 13 (13) 15 ± 11 (25)
Holtzheimer
et al. (2004)
43 47% + – – – Tab two HAMD17 21 ± 6 (8) 23 ± 5 (7) 15 ± 3 (8) 15 ± 3 (7) 6 ± 5 (8) 8 ± 4 (7)
BDI21 28 ± 11 (8) 30 ± 10 (7) 22 ± 2 (8) 24 ± 3 (7) 6 ± 10 (8) 6 ± 9 (7)
Kauffmann
et al. (2004)
52 92% + N/A N/A + Text HAMD21 18 ± 5 (5) 22 ± 6 (7) 12 ± 4 (5) 11 ± 8 (7) 6 ± 4 (5) 11 ± 7 (7)
Koerselman
et al. (2004)
52 56% N/A N/A N/A + Tab four HAMD17 26 ± 6 (26) 26 ± 4 (26) 22 ± 7 (24) 21 ± 7 (25) 4 ± 7 (25) 5 ± 6 (26)
Mosimann
et al. (2004)
62 42% + + 17% N/A + Tab three HAMD21 24 ± 7 (9) 28 ± 5 (15) 20 ± 7 (9) 23 ± 7 (15) 4 ± 7 (9) 5 ± 6 (15)
BDI21 28 ± 11 (9) 30 ± 9 (15) 23 ± 11 (9) 24 ± 13 (15) 5 ± 11 (9) 6 ± 12 (15)
Poulet et al.
(2004)
43 47% N/A N/A N/A +D1 Authors MADRS 36 ± 7 (9) 33 ± 5 (10) 17 ± 9 (9) 16 ± 8 (10) 19 ± 8 (9) 17 ± 7 (10)
BDI13 18 ± 6 (9) 21 ± 8 (10) 11 ± 7 (9) 14 ± 7 (10) 7 ± 7 (9) 7 ± 8 (10)
Rossini et al.
(2005)a
47 80% – – – +D1 Tab two HAMD21 8 ± 7 (47) 13 ± 7 (49)
Rumi et al.
(2005)
39 85% N/A N/A – + Fig two MADRS 39 ± 8 (24) 38 ± 8 (22) 28 ± 12 (24) 14 ± 11 (22) 11 ± 11 (24) 24 ± 10 (22)
Su et al. (2005) 43 73% + + 17% – + All
(Tab two)
HAMD21 23 ± 5 (10) 24 ± 7 (20) 19 ± 8 (10) 11 ± 7 (20) 4 ± 7 (10) 13 ± 7 (20)
BDI21 33 ± 10 (10) 31 ± 9 (20) 29 ± 15 (10) 16 ± 10 (20) 4 ± 13 (10) 15 ± 10 (20)
Avery et al.
(2006)
44 54% + – – + Tab one,
Text
HAMD17 24 ± 3 (33) 24 ± 4 (35) 20 ± 6 (33) 16 ± 8 (35) 4 ± 5 (33) 8 ± 7 (35)
BDI21 28 ± 8 (33) 28 ± 9 (35) 24 ± 8 (33) 17 ± 13 (35) 4 ± 8 (33) 11 ± 12 (35)
Fitzgerald
et al. (2006)
45 62% + + 16% – + Authors,
Tab two


















Table 2 Patient characteristics at baseline and depression scores in the active rTMS and sham groups in N = 40 RCTs (Continued)
BDI21 29 ± 10 (22) 29 ± 10 (25) 22 ± 14 (22) 18 ± 10 (25) 7 ± 12 (22) 11 ± 10 (25)
MADRS 34 ± 6 (22) 34 ± 6 (25) 31 ± 8 (22) 26 ± 10 (25) 3 ± 7 (22) 8 ± 9 (25)
Garcia-Toro
et al. (2006)
48 55% + – – + Tab two HAMD21 25 ± 7 (10) 27 ± 5 (10) 24 ± 8 (10) 20 ± 8 (10) 1 ± 8 (10) 7 ± 7 (10)
Januel et al.
(2006)
38 78% – – N/A – Tab one HAMD17 22 ± 3 (16) 22 ± 4 (11) 17 ± 5 (16) 10 ± 6 (11) 5 ± 4 (16) 12 ± 5 (11)
Anderson
et al. (2007)
47 55% some N/A N/A + Tab one MADRS 28 ± 7 (14) 27 ± 4 (11) 23 ± 10 (14) 15 ± 10 (11) 5 ± 9 (14) 12 ± 9 (11)
Bortolomasi
et al. (2007)
56 58% N/A + 16% N/A + Fig two HAMD24 22 ± 4 (7) 25 ± 8 (12) 18 ± 5 (7) 11 ± 10 (12) 4 ± 5 (7) 14 ± 9 (12)
Fig one BDI21 27 ± 5 (7) 26 ± 7 (12) 22 ± 6 (7) 12 ± 10 (12) 5 ± 6 (7) 14 ± 9 (12)
Herwig et al.
(2007)
50 60% some + 6% N/A +D1 Tab one HAMD21 23 ± 5 (65) 25 ± 5 (62) 14 ± 8 (65) 14 ± 6 (62) 9 ± 7 (59) 11 ± 6 (57)
Tab two BDI21 27 ± 10 (65) 27 ± 9 (62) 18 ± 10 (65) 16 ± 9 (62) 9 ± 10 (59) 11 ± 9 (57)
MADRS 27 ± 6 (65) 28 ± 7 (62) 16 ± 9 (65) 17 ± 8 (62) 11 ± 8 (59) 11 ± 8 (57)
Loo et al.
(2007)
48 47% – + 11% – + Tab two HAMD17 21 ± 4 (19) 19 ± 4 (19) 15 ± 7 (19) 12 ± 6 (19) 6 ± 6 (19) 7 ± 5 (19)
BDI21 34 ± 8 (19) 27 ± 8 (19) 27 ± 10 (19) 18 ± 10 (19) 7 ± 9 (19) 9 ± 9 (19)
MADRS 33 ± 4 (19) 30 ± 4 (19) 27 ± 10 (19) 19 ± 8 (19) 6 ± 9 (19) 11 ± 7 (19)
O’Reardon
et al. (2007)
48 53% some – – – Tab one HAMD17 23 ± 4 (146) 23 ± 3 (155) 19 ± 6 (146) 17 ± 6 (155) 4 ± 5 (146) 6 ± 5 (155)
MADRS 34 ± 6 (146) 33 ± 6 (155) 30 ± 10 (146) 27 ± 11 (155) 4 ± 9 (146) 6 ± 10 (155)
Stern et al.
(2007)
53 – some – – – All (Tab
three)
HAMD21 27 ± 3 (15) 28 ± 4 (30) 27 ± 4 (14) 19 ± 8 (28) 0 ± 4 (14) 9 ± 7 (29)
10Hz 27 ± 3 (15) 28 ± 3 (10) 27 ± 4 (14) 15 ± 6 (10) 0 ± 4 (14) 13 ± 5 (10)
1Hz L 27 ± 3 (15) 28 ± 4 (10) 27 ± 4 (14) 28 ± 6 (8) 0 ± 4 (14) 0 ± 5 (9)
1Hz R 27 ± 3 (15) 28 ± 4 (10) 27 ± 4 (14) 16 ± 5 (10) 0 ± 4 (14) 12 ± 5 (10)
Bretlau et al.
(2008)
55 62% some N/A – +D1 Tab two HAMD17 25 ± 3 (23) 25 ± 3 (22) 19 ± 5 (23) 16 ± 4 (22) 6 ± 4 (23) 9 ± 4 (22)
Mogg et al.
(2008)
54 63% some + 2% N/A + Authors HAMD17 22 ± 5 (30) 21 ± 5 (29) 20 ± 8 (29) 16 ± 9 (28) 2 ± 7 (30) 5 ± 8 (28)
BDI-II21 36 ± 10 (30) 38 ± 11 (29) 31 ± 15 (26) 26 ± 15 (28) 5 ± 13 (28) 12 ± 14 (28)
Notes: All studies included patients with a major depressive episode and/or disorder according to DSM-IV and/or ICD-10 criteria. The mean number of patients per group was used in the final calculations if patients
dropped out throughout the study between baseline and final sessions. All values ending with exactly 0.5 were rounded as follows to reduce the rounding error: zero and uneven numbers upwards (1.5 = 2), even
numbers downwards (2.5 = 2). Standard error of the mean (SEM) was converted to standard deviation (SD) using the formula: SD = SEM × √N (where N = sample size of sham or rTMS groups). ‘All’ indicates that scores
for all independent subgroups within studies were combined. ATreatment-resistance: + are studies in which all patients failed (or showed intolerance to) ≥2 antidepressant trials (of same or different class) of an
adequate dose/length during current or lifetime episode; − are studies in which all patients failed ≤1 antidepressant trials; ‘some’ are studies in which patients failed ≥1 antidepressant trial (these studies were excluded
from all analyses because this category overlapped with the + and – categories); BBipolar (%): + are studies including any proportion of patients with bipolar disorder at baseline; − means that all patients had unipolar
depression (no history of bipolar disorder, mania, hypomania, Axis I disorders); CPsychotic (%): + are studies including any proportion of patients with psychotic features at baseline; − means that all patients had
non-psychotic depression (no history of psychosis, Axis I disorders); DMedication = antidepressants (+means any proportion of patients/study received stable doses, +D1 means that antidepressants were started on day
1 concurrently with rTMS, − means that all patients were unmedicated but some might have received mood stabilizers); EIt was assumed that HAMD21 or BDI21 were used if no further information was provided.; F’Last
session’ refers to the last session of the double-blind phase of a study. aDepression scores were reported as change scores from baseline (baseline – final session). Abbreviations: BDI, Beck Depression Inventory; D1,
antidepressants started on day 1 concurrently with rTMS; DLPFC, dorsolateral prefrontal cortex; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders; Fig, Figure; HAMD, Hamilton Depression Rating Scale;
ICD-10, International Statistical Classification of Diseases and Related Health Problems; L, left DLPFC; MADRS, Montgomery Åsberg Depression Rating Scale; N/A, not reported or inadequate information; R, right DLPFC;
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differences among studies (as opposed to chance) using
the following criteria: 25% (low heterogeneity), 50%
(moderate heterogeneity), and 75% (high heterogeneity)
(Higgins et al. 2003).
Sensitivity and moderator analyses
The stability of the overall mean weighted effect size over
time was investigated as one study at a time was added to
all previous studies (cumulative analysis) and as one study
at a time was removed from the overall analysis (one-study
removed analysis). The moderator analyses were used to
compare the mean weighted effect sizes between sub-
groups of studies with similar characteristics (univariate
subgroup analyses) and to predict change in the weighted
effect sizes based on continuous characteristics of studies
(univariate meta-regressions).
Publication bias analyses
Publication bias occurs when the overall mean weighted
effect size is inflated in a meta-analysis due to a selection
of studies biased towards those with larger (and statisti-
cally significant) effect sizes (Borenstein et al. 2009). Al-
though a novel literature search was not conducted in
the current study, publication bias was assessed using
methods available in the CMA software. The Rosenthal’s
Fail-Safe N (Rosenthal 1979) was used to compute the
theoretical number of unpublished studies with low effect
sizes required to remove the significance of the overall
mean weighted effect size. The Duval and Tweedie’s Trim-
and-Fill analysis (Duval and Tweedie 2000) was used to
test if effect sizes plotted against their variability (standard
error of the mean, SEM) on a so-called funnel plot (Sterne
and Egger 2001) are symmetrically distributed around the
overall mean weighted effect size. Finally, the Begg and
Mazumdar Rank Order Correlation (Kendall’s tau b)
between the standardised effect sizes vs. SEM in each
study (Begg and Mazumdar 1994) and the Egger’s re-
gression of 1/SEM (predictor) on the standardised effect
sizes (Egger et al. 1997) were used to test if studies with
lower effect sizes differ systematically (significantly) from
studies with higher effect sizes. It was assumed that publi-
cation bias is present if Fail-Safe N is low, the funnel plot
is asymmetrical, Begg and Mazumdar correlation is sig-
nificant, and the intercept of Egger’s regression line signifi-
cantly deviates from zero (Borenstein et al. 2009).
Results
The N = 40 primary RCTs included in the current
meta-analysis were conducted in 15 countries, mostly
in Western Europe (N = 20 RCTs, 50%), USA (N = 13
RCTs, 32%), and Australia (N = 6 RCTs, 15%). Accord-
ing to the overall analysis, there was a significant reduc-
tion in the mean depression scores from baseline tofinal, favouring rTMS over sham, in N = 40 RCTs based
on a total of 1583 patients (844 in the active rTMS and
739 in sham groups; for the forest plot see Additional
file 1: Figure S1). However, the magnitude of such an
overall short-term antidepressant effect of rTMS was
only moderate (the overall mean weighted effect size
d = −.54, 95% CI: −.68, −.41; ptwo-tailed < .001 and g = −.53;
95% CI: −.66, −.40; ptwo-tailed < .001). Since d and g were
similar in magnitude, it is unlikely that d was inflated in
the mostly small-sample primary studies included in this
analysis. Thus, all subsequent analyses were performed
using Cohen’s d alone.
There was little heterogeneity among the 40 effect
sizes due to real (methodological) differences among
studies (Q = 54, df = 39, ptwo-tailed = .054, I
2 = 28%). The
overall effect size was low-moderate as studies were added
over time cumulatively (Additional file 1: Figure S2) and
was not dependent on any one study alone (as one study at
a time was removed from the analysis; Additional file 1:
Figure S3). It is also unlikely that publication bias occurred
because Fail-Safe N of 908 was high and Begg and Mazum-
dar correlation and Egger’s regression were not statistically
significant (ptwo-tailed = .633 and ptwo-tailed = .112 respect-
ively). Although the funnel plot was not symmetrical
(Additional file 1: Figure S4), the overall mean weighted
d corrected for seven studies theoretically missing from
the analysis indicated that antidepressant effect was still
present in the data favouring rTMS over sham (corrected
overall mean weighted d = −.42, 95% CI: −.57, −.28).
The short-term antidepressant effect favouring rTMS
over sham was observed when studies were grouped
according to each depression scale separately: HAMD
used in 36 (90%) RCTs (the overall mean weighted
d = −.54, 95% CI: −.69, −.40; ptwo-tailed < .001), BDI used
in 17 (42%) RCTs (the overall mean weighted d = −.42,
95% CI: −.58, −.26; ptwo-tailed < .001), and MADRS in 12
(30%) RCTs (the overall mean weighted d = −.44, 95%
CI: −.69, −.20; ptwo-tailed < .001).
The N = 40 RCTs utilised the following combinations
of frequency-location of rTMS: HFL in N = 33 (82%)
RCTs, LFR in N = 5 (12%) RCTs, bilateral or sequential
(left then right) in N = 4 (10%) RCTs, and low-frequency
left in N = 3 (8%) RCTs. Inspection of the 33 effect sizes
in HFL studies revealed that one RCT (Stern et al. 2007)
produced a significantly higher effect size (d = −2.93)
compared to all other 32 RCTs (d = −.47) and thus was
classified as a statistical outlier. Since the inclusion of
this study would inflate all effect sizes in the HFL analysis,
this study was removed from all subsequent analyses to
maintain statistical conservativeness (for more details see
Additional file 1: Figure S5; note that the overall effect size
based on all three active rTMS subgroups in this RCT was
not classified as an outlier and thus the study was kept in
the overall analysis of N = 40 RCTs presented above). The
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sham was observed in HFL studies (the overall mean
weighted d = −.47, 95% CI: −.61, −.33; ptwo-tailed < .001;
N = 32 RCTs), LFR studies (the overall mean weighted
d = −1.21, 95% CI: −1.85, −.56; ptwo-tailed < .001; N = 5
RCTs), and bilateral or sequential studies (the overall mean
weighted d = −.45, 95% CI: −.82, −.09; ptwo-tailed = .015;
N = 4 RCTs) but not in the low-frequency left rTMS
studies (the overall mean weighted d = −.35, 95% CI: −.97,
.27; ptwo-tailed = .268; N = 3 RCTs). Due to a low number
of studies in the other subgroups, further analyses were
conducted only on the largest subgroup of HFL studies
(N = 32 RCTs).
The antidepressant effect favouring HFL rTMS over
sham in 32 RCTs was based on 1279 patients (Figure 2).
There was little heterogeneity among the 32 effect sizes
attributable to real differences among HFL studies
(Q = 39, df = 31, ptwo-tailed = .154, I
2 = 20%). The over-
all effect size was consistently low-moderate as studies
were added over time and was not dependent on any one
study alone (for cumulative and one-study removed analyses
see the Additional file 1: Figures S6 and S7). It is unlikely that
publication bias occurred because Fail-Safe N of 425 was
high, funnel plot was symmetrical (Figure 2), and Begg and
Mazumdar correlation and Egger’s regression were not
statistically significant (ptwo-tailed = .808 and ptwo-tailed = .322
respectively).
Grouping of HFL studies based on the clinical character-
istics of patients revealed that the majority of those studies
included patients with treatment-resistance, on antidepres-
sants (at stable doses in N = 20 RCTs or started concur-
rently with rTMS in N = 5 RCTs), with bipolar depression,
and without psychotic features (Table 3). The proportions
of bipolar and psychotic patients per study were mostly low
(<50%) except for one study conducted on bipolar patients
only (Table 2). Most patients in the HFL studies were
middle-aged or older (39–62 years old on average) and
about half were female (Table 3). The most common rTMS
parameters in the HFL studies were: frequency of 10 Hz,
stimulus intensity equivalent to the resting motor threshold
of 80-110%, 10 stimulation sessions, 1600 stimuli/session
(or 16000 stimuli/study), 20 trains/session, 30 s inter-train
interval, and a 70 mm coil diameter (Table 3). Most studies
used the figure-of-eight shape of the stimulating coil and a
90 degree angle from scalp during sham (Table 3).
According to our univariate classification of studies, the
antidepressant effect favouring HFL rTMS over sham
was independent of treatment-resistance, treatment with
antidepressants, and bipolar diagnoses (Table 3). The anti-
depressant effect was also present in studies with non-
psychotic patients and in studies utilising figure-of-eight
coils (Table 3). The magnitude of the antidepressant effect
was similar in studies with sham coils and coils tilted at 90
degrees from scalp (Table 3).Except for one, all univariate random-effects meta-
regressions were not statistically significant. Thus, the
mean weighted d per study could not be univariately pre-
dicted by any of the following study characteristics in HFL
rTMS studies: mean age of all patients per study, fre-
quency of stimulation, stimulus intensity (% motor thresh-
old), number of sessions, stimuli/session, stimuli/study,
trains/session, and inter-train interval. However, a signifi-
cantly higher antidepressant effect was observed in HFL
studies with higher proportion of female patients (Table 3,
Figure 3). The predictor (% female patients) explained
97% of the between-study variance in effect sizes in the
HFL rTMS studies (Figure 3).
Discussion
The results of the current meta-analysis quantitatively
supplement the narrative findings of Dell’Osso and col-
leagues (2011). Specifically, we confirm that rTMS had a
significant, but only moderate, short-term antidepressant
effect in the treatment of major depression based on data
from N = 40 RCTs published between 1997–2008 and se-
lected from 13 past meta-analyses on this topic (published
until 2010). This result is based on data from 1583 pa-
tients tested in 15 countries. A similar result was also
observed based on the newer RCTs published between
2010–2013 (Kedzior et al. 2014). Although the clinical
relevance of a moderate effect size is questionable, the
antidepressant effect of rTMS was relatively robust as new
studies were added to the existing ones (from 2000–2008).
It remains to be seen if rTMS also has stable longitudinal
antidepressant properties. The moderate effect size is
probably unrelated to heterogeneous statistical approaches
used in the past meta-analyses because it was also ob-
tained in the current study conducted using one method
of meta-analysis.
The current study shows that depression scores were
reduced after rTMS regardless of depression scale used.
Thus, the often self-administered BDI scale appears to be
as effective at measuring depression as the widely used
HAMD that is clinician-administered and has the best
psychometric properties of the three scales (Trajkovic
et al. 2011). However, only moderate effect sizes might
have resulted from combining depression scores from all
scales and/or different versions of HAMD and BDI scales
(Table 2) in the current analysis. Thus, if adequate number
of studies is available, future meta-analyses should be con-
ducted on data based on one version of the same scale to
reduce the variability of depression scores and possibly in-
crease the overall effect sizes.
Similarly to the other meta-analyses (Dell’Osso et al.
2011), the current results indicate that the short-term anti-
depressant effect was observed in studies utilising HFL
rTMS and also LFR and bilateral designs (Table 3). The
LFR and bilateral stimulation need to be investigated in
Study name Outcome Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value Sham rTMS
George et al. (1997) HAMD -1.44 -2.73 -0.16 0.028 5 7
Avery et al. (1999) Combined -0.50 -2.23 1.23 0.572 2 4
Kimbrell et al. (1999) HAMD 0.24 -1.20 1.68 0.744 3 5
Loo et al. (1999) Combined 0.25 -0.67 1.18 0.592 9 9
Padberg et al. (1999) HAMD -0.40 -1.54 0.74 0.493 6 6
Berman et al. (2000) HAMD -1.21 -2.17 -0.26 0.013 10 10
Eschweiler et al. (2000) Combined -1.35 -2.62 -0.08 0.038 5 7
George et al. (2000) all HAMD -0.70 -1.48 0.08 0.080 10 20
Garcia-Toro et al. (2001a) Combined -0.63 -1.31 0.05 0.071 18 17
Garcia-Toro et al. (2001b) Combined -0.44 -1.29 0.41 0.309 11 11
Manes et al. (2001) HAMD -0.30 -1.18 0.58 0.505 10 10
Boutros et al. (2002) HAMD -0.25 -1.20 0.70 0.606 7 11
Padberg et al. (2002) Combined -0.99 -1.92 -0.06 0.038 10 10
Fitzgerald et al. (2003) Combined -0.39 -1.02 0.23 0.220 20 20
Höppner et al. (2003) Combined 0.19 -0.70 1.08 0.676 10 10
Nahas et al. (2003) HAMD 0.09 -0.73 0.91 0.828 12 11
Buchholtz et al. (2004) HAMD 0.14 -0.95 1.24 0.796 7 6
Holtzheimer et al. (2004) Combined -0.22 -1.24 0.80 0.674 8 7
Koerselman et al. (2004) HAMD -0.15 -0.70 0.40 0.584 25 26
Mosimann et al. (2004) Combined -0.12 -0.95 0.71 0.774 9 15
Poulet et al. (2004) Combined 0.13 -0.77 1.04 0.772 9 10
Rossini et al. (2005) HAMD -0.71 -1.13 -0.30 0.001 47 49
Rumi et al. (2005) MADRS -1.23 -1.87 -0.60 0.000 24 22
Su et al. (2005) all Combined -1.14 -1.95 -0.33 0.006 10 20
Avery et al. (2006) Combined -0.67 -1.16 -0.18 0.007 33 35
Anderson et al. (2007) MADRS -0.78 -1.60 0.04 0.063 14 11
Bortolomasi et al. (2007) Combined -1.20 -2.20 -0.19 0.020 7 12
Herwig et al. (2007) Combined -0.17 -0.54 0.19 0.355 59 57
Loo et al. (2007) Combined -0.34 -0.98 0.30 0.298 19 19
O'Reardon et al. (2007) Combined -0.30 -0.53 -0.08 0.009 146 155
Bretlau et al. (2008) HAMD -0.75 -1.35 -0.15 0.015 23 22
Mogg et al. (2008) Combined -0.46 -0.99 0.07 0.087 29 28
-0.47 -0.61 -0.33 0.000
-3.00 -1.50 0.00 1.50 3.00
rTMS effective sham effective
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Figure 2 (See legend on next page.)
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Figure 2 Random-effects meta-analysis of depression scores (baseline-final) after HFL rTMS compared to sham in N = 32 studies. Notes:
‘All’ refers to all patients in two HFL rTMS groups who received rTMS with two different stimulation frequencies. ‘Combined’ in the column
‘Outcome’ indicates that more than one depression scale was used in a study and the effect sizes according to the multiple scales were
combined into one. The mean number of patients per group was used in the final calculations if patients dropped out throughout the study
between baseline and final sessions. The forest plot (top) shows the weighted effect size d (box) and its 95% CI (vertical line through the box) for
each study in the analysis. The diamond depicts the overall mean weighted d of all studies and its 95% CI (width of the diamond). The mean
depression scores (baseline – final) were significantly reduced after HFL rTMS compared to sham in 32 studies (overall mean weighted d = −.47,
95% CI: −.61, −.33). The funnel plot (bottom) shows the effect size d versus standard error in each study in the analysis. The plot was symmetrical
around the overall mean weighted d suggesting that there was little evidence for publication bias in the current meta-analysis. Abbreviations: CI,
confidence interval; HAMD, Hamilton Depression Rating Scale; HFL, high-frequency left rTMS; MADRS, Montgomery Åsberg Depression Rating
Scale; rTMS, repetitive transcranial magnetic stimulation; Std diff, standardised mean difference (Cohen’s d).
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ical effectiveness similar to that of HFL designs (Fitzgerald
and Daskalakis 2012). In general, while a single study de-
sign might not be used as paradigmatic (Herrmann and
Ebmeier 2006), combinations of various rTMS parameters
appear to facilitate the antidepressant properties of rTMS.
The novel, unexpected finding of the current meta-
analysis is that the antidepressant effect of HFL rTMS was
higher in RCTs with higher proportion of female patients
(Figure 3). To our knowledge this effect was not tested in
any of the past 13 meta-analyses nor in the newer meta-
analyses published since, except for our follow-up analysis
to the current study (for review see Kedzior et al. 2014).
According to our follow-up meta-analysis, the short-term
antidepressant effect of rTMS with any frequency/location
was also higher with higher proportion of female patients
in N = 53 RCTs published between 1997–2013 (Kedzior
et al. 2014). The finding that the response to rTMS might
depend on gender is particularly interesting because twice
as many women as men are diagnosed with depression
worldwide (Bromet et al. 2011). However, this result needs
to be interpreted with some caution because the univari-
ate meta-regression analysis did not control for any other
possible confounders. Therefore, it is possible that female
patients systematically differed from the male patients in
terms of age, severity of resistance, or design/rTMS pa-
rameters of the study in which they have participated.
Thus, the apparent relationship between gender and effect
size could be secondary to those and other factors not
taken into account in our analysis. In support of this argu-
ment, the open-label studies and smaller RCTs in medi-
cated or unmedicated patients showed that young age and
lower severity of treatment resistance were associated with
an improved antidepressant outcome of rTMS controlling
for other predictors (Brakemeier et al. 2007; Brakemeier
et al. 2008; Fregni et al. 2006) and responders to rTMS
were significantly younger than non-responders (Kozel
et al. 2000). In female patients reduction in depression
was associated with young age and a stage of menstrual
cycle (Huang et al. 2008). Treatment-resistant, unipolar fe-
male patients also showed both a short-term and also along-term (up to 24 weeks) antidepressant response to the
combination of 10 sessions of LFR rTMS and two sessions
of partial sleep deprivation (Krstic et al. 2014). A better
outcome with lower degree of treatment resistance in
the current episode was observed univariately in non-
psychotic unipolar patients according to a large RCT
(O’Reardon et al. 2007) and an open-label extension
trial (Lisanby et al. 2009). The open-label extension of
another large RCT (George et al. 2010) showed that ex-
tending the stimulation period for more than five weeks
and changing the stimulation site improved remission
rates in patients who failed to meet the minimal re-
sponse criteria during the RCT (McDonald et al. 2011).
One way of dealing with possible multiple predictors of
the antidepressant response to rTMS would be to in-
clude such predictors in a multivariate meta-regression
analysis. However, such an analysis was not conducted
here because not all studies reported all their patient/
rTMS characteristics (see Tables 1–3) leading to missing
values on many predictors and thus a low ratio of stud-
ies to possible predictors. In fact, the effect sizes should
be compared between male and female patients while
controlling for multiple predictors in the future RCTs
due to availability of individual patient data rather than
group data used in meta-analyses.
It is unlikely that the significant meta-regression was due
to a statistical artifact and/or the largest RCT (O’Reardon
et al. 2007) in the current meta-analysis. Compared to a
traditional (unweighted) regression analysis, the slope of
regression line was influenced by study weights rather than
effect sizes alone in the current analysis. Therefore, studies
with higher precision (and weight) had a higher influence
on the slope of the regression line than (presumably)
lower-quality studies with a high variability of scores. The
plot of the weighted effect sizes versus the proportion of
female patients (Figure 3) suggests that the relationship be-
tween the two variables was reasonably linear and not
influenced by any major outliers. The outcome of the ana-
lysis also remained unchanged after the study with the lar-
gest weight (O’Reardon et al. 2007) was removed from the
analysis (see the Additional file 1: Figure S8). Finally, the
Table 3 Univariate random-effects subgroup analyses and meta-regressions in N = 32 HFL rTMS studies
Study subgroupsa N studies (%)b d (95% CI) ptwo-tailed Meta-regression
predictors
N studiesb Mode Range Regression
line slope
ptwo-tailed
Treatment resistance 13 Patient characteristics
YES (all failed ≥2 AD trials) 10 (77%) -.56 (−.81, −.32) <.001* Female patients (%) 32 47, 50 22-92 .003*
NO (all failed ≤1 AD trials) 3 (23%) -.58 (−.90, −.26) <.001* Mean age (years) 32 43, 44 39-62 .194
Antidepressants 32 Bipolar patients (%) 24 0 0-100 .211
YES (any % of patients) 25 (78%) -.51 (−.68, −.35) <.001* Psychotic patients (%) 14 0 0-8 .789
Stable dose 20 (80%) -.54 (−.74, −.34) <.001* rTMS parameters
Started with rTMS 5 (20%) -.43 (−.75, −.12) .007* Frequency (Hz) 32 10 5-20 .824
NO (all patients) 7 (22%) -.33 (−.53, −.14) .001* Motor threshold (%) 32 80, 90, 110 80-120 .984
Bipolar depression 24 Total sessions 32 10 5-20 .813
YES (any % of patients) 16 (67%) -.39 (−.62, −.16) .001* Stimuli/session 20 1600 250-3000 .021*c
NO (all patients) 8 (33%) -.45 (−.62, −.28) <.001* Total stimuli/study 20 16000 1250-60000 .124
Psychotic depression 14 Trains/session 28 20 5-100 .217
YES (any % of patients) 3 (21%) -.73 (−1.78, .33) .177 Inter-train interval (s) 31 30 8-60 .680
NO (all patients) 11 (79%) -.59 (−.81, −.36) <.001*
Coil-type 30
Figure-of-eight 28 (93%) -.50 (−.66, −.34) <.001*
Circular 2 (7%) -.59 (−1.59, .42) .254
Coil angle sham 32
0° (inactive coil) 2 (6%) -.33 (−.85, .19) .217
0° (sham coil) 5 (16%) -.63 (−.98, −.28) <.001*
45° 12 (38%) -.27 (−.50, −.04) .022*
90° 13 (41%) -.61 (−.82, −.40) <.001*
Notes: aThere were no statistically significant differences in effect sizes between subgroups. Subgroups were compared using the mixed-effect model (random-
effects model was used to compute the overall mean weighted d in each subgroup, overall mean weighted d of subgroups were compared using the fixed-effect
model because the number of subgroups was fixed). bNot all studies reported the characteristics investigated in this table. cUnlike % female patients, the slope of
regression line of stimuli/session on weighted d was driven by the largest study in the current analysis (O’Reardon et al. 2007). After removal of this study the
p-value of the slope of regression line was .061. Abbreviations: AD, antidepressant; d, weighted standardised mean difference (Cohen’s d); HFL, high-frequency left
rTMS; rTMS, repetitive transcranial magnetic stimulation. *p < .05
Kedzior and Reitz BMC Psychology 2014, 2:39 Page 14 of 19
http://www.biomedcentral.com/2050-7283/2/39predictor ‘proportion of female patients/study’ explained a
high amount (97%) of between-study variance in the
current analysis.
The relatively low effect sizes in the current and other
meta-analyses could have been due to differences in the
sham conditions and thus different levels of blinding in-
tegrity. Such integrity is important because the effect
sizes in our analysis were computed based on the change
in depression scores from baseline to final in rTMS
compared to sham conditions. A recent meta-analysis of
blinding integrity showed that only very few studies re-
ported their blinding success and that the development
of novel sham strategies, such as shielded magnetic coils,
might help to adequately conceal the treatment alloca-
tion (Berlim et al. 2013). Based on our data, the most
commonly used sham technique was tilting the active
coil at the 90 degree angle from scalp in studies published
between 1997–2008. Although it has been argued thattilted active coils could cause some cortical stimulation
(Mitchell and Loo 2006), the current results showed that
the effect sizes were similar in studies with sham coils
(overall d = −.63) and coils tilted at 90 degree angle from
scalp (overall d = −.61; Table 3) not controlling for other
study characteristics. Thus, it remains to be seen if better
blinding integrity could contribute to higher antidepres-
sant effect of rTMS in the future RCTs.
The antidepressant effect of HFL rTMS was probably
not secondary to concurrent treatment with antidepres-
sants because it was observed in a group of studies that
included unmedicated patients and in studies with treat-
ment resistant patients. In the latter studies, rTMS might
have acted as a ‘key-like’ mechanism by unlocking the un-
responsive pathways in the DLPFC and beyond, and thus
aiding the action of antidepressants. In general, the high-
frequency rTMS is thought to reverse the hypo-excitability
of the left DLPFC (Daskalakis et al. 2008). However, since
Regression of        Female on Std diff in means






















Figure 3 Univariate random-effects meta-regression of % female patients (predictor) on the weighted effect sizes d (outcome) in
N = 32 HFL rTMS studies. Notes: The figure shows a scatterplot of weighted d/study (Y-axis) versus proportion of female patients/study (X-axis).
The circles depict individual studies (the larger the diameter of the circle the larger the study weight). The slope of the regression line (B = −.01)
was statistically significant (ptwo-tailed = .003) indicating that depression scores were significantly reduced after HFL rTMS compared to sham in
studies with higher proportion of female patients. The predictor (% female patients) explained 97% of the between-study variance in weighted
d according to the following formula: R2 = 1-(T2model/T2total), where T2model (here = .00093) is the between-study variance in the weighted d
unexplained by the regression model containing the predictor and T2total (here = .029) is the within- and between-study variance. The removal
of the study with the largest weight (O’Reardon et al. 2007) did not change the outcome of this analysis (B = −.01, slope ptwo-tailed = .006; for a
scatterplot see the Additional file 1). Abbreviations: HFL, high-frequency left rTMS; rTMS, repetitive transcranial magnetic stimulation; Std diff,
standardised mean difference (Cohen’s d).
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depression, rTMS might also affect deeper neural areas be-
yond the stimulation site involved in aetiology of de-
pression (Kedzior et al. 2012). Rather than affecting any
particular structures, rTMS could aid the action of anti-
depressants by altering the circuit level connectivity be-
cause depression is not associated with abnormalities at
any specific location in the brain (Pandya et al. 2012).
For example, depending on the number of sessions,
stimuli, and frequency, rTMS could induce changes in
cortical inhibition or excitation by modifying synaptic
release or reuptake of neurotransmitters targeted by an-
tidepressants depending on their class (de Jesus et al.
2014; Medina and Tunez 2013). The response to antide-
pressants in rTMS studies might also depend on the
waveform of stimuli (biphasic vs. monophasic) that are
associated with differential changes in cortical excitabil-
ity (Groppa et al. 2012; Loo and Mitchell 2005).
The reduction in depression after HFL rTMS might
have been concurrent or even secondary to improvements
in cognitive functioning (Kedzior et al. 2012). Indeed, a
systematic review showed that rTMS characteristics, such
as 10–20 Hz frequency, 10–15 sessions, and stimulus in-
tensity with 80-110% resting motor threshold were associ-
ated with cognitive improvements in psychiatric disorders
(Guse et al. 2010). These characteristics were also com-
monly used in the HFL rTMS studies in the current
meta-analysis. Importantly, the cognitive effects of rTMSdepended on the correct positioning of the coil (Guse
et al. 2010), a factor that was not controlled for in the
current meta-analysis. According to Table 1, most studies
included in the current analysis used the ‘5 cm’ rule for
coil positioning. Using other localisation methods, such
as the magnetic resonance image (MRI)-guided neuro-
navigation, could further improve the antidepressant ef-
fect of rTMS (Rusjan et al. 2010).
There were a number of limitations in the current
meta-analysis. Firstly, non-response rates and/or drop-
out rates were not considered in our analyses. However,
if reported, depression scores based on the intention-to-
treat analysis were used in the current study. Secondly,
treatment resistance should be defined as a ‘failure to re-
spond to at least two antidepressants of different classes
during current episode of depression’ (Berlim and Turecki
2007). Due to inadequate information provided in some
studies we have used a more liberal version of this defin-
ition to classify treatment resistance (failure to respond to
at least two antidepressants of the same or different classes
during any current or past episode of depression). Thirdly,
we did not control for other medications and/or affective
disorders although evidence from a large RCT suggests
that absence of comorbid anxiety is associated with an
improved outcome of rTMS (Lisanby et al. 2009). Finally,
the current analysis did not formally assess all measures
of quality of studies according to The Cochrane Collab-
oration (Higgins et al. 2011). These measures are seven
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allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting, and other bias) that
should be assessed using a three point system (low risk,
high risk, unclear risk) to evaluate the risk of bias (or
quality of studies) included in systematic reviews. Three
of these seven domains (randomisation, blinding, and
withdrawals/drop-outs) can also be quantitatively assessed
using the Jadad Scale, which has acceptable psychometric
properties (construct validity and inter-rater agreement)
(Jadad et al. 1996). A review of 965 systematic reviews
(published between 1995–2002) revealed that no consen-
sus exists with regards to the assessment of quality of pri-
mary studies (Moja et al. 2005). Although 94% of 809
Cochrane systematic reviews indeed assessed the quality
of studies (compared to only 60% of non-Cochrane re-
views), only approximately 50% of all reviews linked such
an assessment to the results of their analyses (Moja et al.
2005). The current study utilised all formal approaches to
the assessment of quality of studies as those most com-
monly applied in the 965 systematic reviews: explicitly
listed exclusion/inclusion criteria, exploration of hetero-
geneity (subgroup analyses, meta-regressions), sensitivity
analysis (identification of statistical outliers, one-study re-
moved, and cumulative analyses), and a weighing method
favouring studies with higher precision (Moja et al. 2005).
The primary studies included in our analysis were of high
quality based on the specific inclusion criteria: randomisa-
tion (including inactive sham group), blinding (sham
stimulation applied at the same location as active rTMS),
and reduction in other biases (carry-over effects elimi-
nated due to inclusion of parallel stimulation data). We
have addressed the difficulties with double-blinding of pa-
tients and staff in rTMS research by comparing the results
based on different methods of blinding in the subgroup
analysis (Table 3). Finally, the quality of studies was
measured indirectly using the inverse-variance weighing
method: Studies with higher variability of depression
scores (and presumably lower quality) had lower weights
and thus a low contribution to the magnitude of the over-
all antidepressant effect of rTMS and vice-versa.
Conclusions
Daily rTMS (with any parameters) has a moderate, short-
term antidepressant effect according to N = 40 RCTs (pub-
lished between 1997–2008) and based on data from 1583
patients tested in 15 countries. This effect may not be sec-
ondary to treatment with antidepressants because it was
observed in a subgroup of studies with unmedicated pa-
tients and treatment-resistant patients. Univariately, the
short-term clinical efficacy of particularly the HFL rTMS
may be better in female patients not controlling for any
other study parameters. When adequate volume of datafrom primary RCTs becomes available, the future meta-
analyses should focus on identifying the best combination
of patient characteristics (demographic and clinical) and
rTMS parameters that could further improve the short-
term antidepressant response to rTMS.
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